Apoptosis primarily accounts for the growth-inhibitory properties of sulindac metabolites and involves a mechanism that is independent of cyclooxygenase inhibition, cell cycle arrest, and p53 induction - PubMed (original) (raw)
. 1997 Jun 15;57(12):2452-9.
Affiliations
- PMID: 9192825
Apoptosis primarily accounts for the growth-inhibitory properties of sulindac metabolites and involves a mechanism that is independent of cyclooxygenase inhibition, cell cycle arrest, and p53 induction
G A Piazza et al. Cancer Res. 1997.
Abstract
Sulindac causes regression of and prevents recurrence of colonic adenomas in patients with familial adenomatous polyposis. Although cell cycle arrest and apoptosis have been proposed, the mechanism of action is poorly understood. In this study, we characterized the growth-inhibitory effects of active metabolites of sulindac in cultured colon adenocarcinoma cells by determining the contribution of apoptosis and cell cycle arrest and the requirement for cyclooxygenase (COX) inhibition and p53 involvement and compared the effects of sulindac metabolites with the chemotherapeutic drug, 5-fluorouracil (5-FU). Time course and dose-response experiments demonstrated that increased apoptosis paralleled the growth-inhibitory effects of the sulfide and sulfone. A relationship among a series of nonsteroidal anti-inflammatory drugs was observed between potency for growth inhibition and ability to induce apoptosis but not potency to inhibit COX. For example, the sulfone was at least 5000-fold less potent than the sulfide for inhibiting COX but only 6.5-fold less potent for inducing apoptosis. Moreover, the prostaglandin analogue, dimethyl-prostaglandin E2, failed to reverse the apoptosis-inducing effects of the sulfide. Sulindac metabolites caused G1 cell cycle arrest in proliferating cells but were comparably effective in nonproliferating cells. In contrast, 5-FU treatment was less effective in nonproliferating cells. Combined treatment with sulindac metabolites and 5-FU did not result in an additive apoptotic response. Treatment of cells with 5-FU increased p53 protein levels, whereas sulindac metabolites did not induce expression. Saos-2 cells, which lack p53, responded to sulindac metabolites but not 5-FU. These results show that apoptosis primarily contributes to growth inhibition by sulindac metabolites. The biochemical pathway does not require COX inhibition or p53 induction and appears to be fundamentally different from the apoptotic response to 5-FU.
Similar articles
- Dual antitumor effects of 5-fluorouracil on the cell cycle in colorectal carcinoma cells: a novel target mechanism concept for pharmacokinetic modulating chemotherapy.
Yoshikawa R, Kusunoki M, Yanagi H, Noda M, Furuyama JI, Yamamura T, Hashimoto-Tamaoki T. Yoshikawa R, et al. Cancer Res. 2001 Feb 1;61(3):1029-37. Cancer Res. 2001. PMID: 11221829 - Regulation of 15-hydroxyprostaglandin dehydrogenase (15-PGDH) by non-steroidal anti-inflammatory drugs (NSAIDs).
Tai HH, Chi X, Tong M. Tai HH, et al. Prostaglandins Other Lipid Mediat. 2011 Nov;96(1-4):37-40. doi: 10.1016/j.prostaglandins.2011.06.005. Epub 2011 Jul 6. Prostaglandins Other Lipid Mediat. 2011. PMID: 21763448 Review. - Colon cancer prevention by NSAIDs: what is the mechanism of action?
Ahnen DJ. Ahnen DJ. Eur J Surg Suppl. 1998;(582):111-4. doi: 10.1080/11024159850191544. Eur J Surg Suppl. 1998. PMID: 10029375 Review.
Cited by
- NF-κB pathway in colitis-associated cancers.
Viennois E, Chen F, Merlin D. Viennois E, et al. Transl Gastrointest Cancer. 2013 Jan 1;2(1):21-29. doi: 10.3978/j.issn.2224-4778.2012.11.01. Transl Gastrointest Cancer. 2013. PMID: 23626930 Free PMC article. - Sporadic adenomatous polyp regression with exisulind is effective but toxic: a randomised, double blind, placebo controlled, dose-response study.
Arber N, Kuwada S, Leshno M, Sjodahl R, Hultcrantz R, Rex D; Exisulind Study Group. Arber N, et al. Gut. 2006 Mar;55(3):367-73. doi: 10.1136/gut.2004.061432. Epub 2005 Sep 8. Gut. 2006. PMID: 16150858 Free PMC article. Clinical Trial. - A cyclooxygenase-2 inhibitor (SC-58125) blocks growth of established human colon cancer xenografts.
Williams CS, Sheng H, Brockman JA, Armandla R, Shao J, Washington MK, Elkahloun AG, DuBois RN. Williams CS, et al. Neoplasia. 2001 Sep-Oct;3(5):428-36. doi: 10.1038/sj.neo.7900177. Neoplasia. 2001. PMID: 11687954 Free PMC article. - Evidence for colorectal cancer cell specificity of aspirin effects on NF kappa B signalling and apoptosis.
Din FV, Dunlop MG, Stark LA. Din FV, et al. Br J Cancer. 2004 Jul 19;91(2):381-8. doi: 10.1038/sj.bjc.6601913. Br J Cancer. 2004. PMID: 15188000 Free PMC article. - Phase I clinical trial of weekly docetaxel and exisulind, a novel inducer of apoptosis.
Garcia AA, Iqbal S, Quinn D, Edwards S, Lenz HJ, Weber J. Garcia AA, et al. Invest New Drugs. 2006 Jan;24(1):79-83. doi: 10.1007/s10637-005-4542-0. Invest New Drugs. 2006. PMID: 16379039 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Research Materials
Miscellaneous